Market Place
Sourcing Support
Patient Death Clouds Positive Data for Beam`s Sickle Cell Therapy
06 Nov 2024 //
BIOSPACE
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
28 Feb 2024 //
PRESS RELEASE
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
27 Feb 2024 //
PRESS RELEASE
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
05 Feb 2024 //
PRESS RELEASE
Beam Therapeutics Appoints Christi Shaw to its Board of Directors
14 Dec 2023 //
PRESS RELEASE
Beam Therapeutics Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
PRESS RELEASE
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
08 Nov 2023 //
PRESS RELEASE
Beam offloads Verve rights to Lilly for up to $600M
31 Oct 2023 //
FIERCE BIOTECH
Beam Therapeutics Presents Data Highlighting Utility and Durability of BEAM-301
25 Oct 2023 //
PRESS RELEASE
Beam Therapeutics Announces Portfolio Prioritization & Strategic Restructuring
19 Oct 2023 //
PRESS RELEASE
Beam lays off 20% of staff and culls CAR-T work to save cash
19 Oct 2023 //
FIERCE BIOTECH
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302
07 Sep 2023 //
PRESS RELEASE
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201
05 Sep 2023 //
PRESS RELEASE
Beam Therapeutics Reports Pipeline Updates and Q2 2023 Financial Results
08 Aug 2023 //
PRESS RELEASE
Beam takes time to clinic;Aspen gets clearance to test Parkinson`s cell therapy
08 Aug 2023 //
ENDPTS
Beam shareholders incur further losses as stock declines 4.6% this week
09 Jul 2023 //
YAHOO FINANCE
After a Significant Correction, Beam Therapeutics Looks Interesting Again
15 Jun 2023 //
REALMONEY
Beam Therapeutics to Participate in Upcoming May Investor Conferences
17 May 2023 //
PRESS RELEASE
Beam Therapeutics to Participate in RBC Capital Markets Healthcare Conference
11 May 2023 //
PRESS RELEASE
Beam Therapeutics Reports Pipeline Updates and Q1 2023 Financial Results
10 May 2023 //
PRESS RELEASE
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
01 Mar 2023 //
PRESS RELEASE
Beam to Participate in SVB Securities Virtual Global Biopharma Conference
07 Feb 2023 //
PRESS RELEASE
The CFO of Beam Therapeutics Inc. (NASDAQ:BEAM) sells 47,195 shares of stock.
26 Jan 2023 //
BESTSTOCKS
Beam hopes to sidestep sickle cell peers with gene editing
10 Jan 2023 //
FIERCEBIOTECH
Beam Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
PRESS RELEASE
Beam Therapeutics` Market Cap Dips US$121m, Insiders Who Sold Offset Some Losses
19 Dec 2022 //
SIMPLYWALL
Beam Presents First In Vivo Proof of Concept Preclinical Data on ESCAPE Platform
10 Dec 2022 //
GLOBENEWSWIRE
FDA lifts pause on Beam plans to test base editing cancer therapy
03 Dec 2022 //
BIOPHARMADIVE
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
30 Nov 2022 //
PRESS RELEASE
Beam Enrolls First Patient in BEACON Trial of BEAM-101
14 Nov 2022 //
PRESS RELEASE
Beam Therapeutics to Participate in Upcoming Investor Conferences
09 Nov 2022 //
PRESS RELEASE
Beam Reports Third Quarter 2022 Financial Results
07 Nov 2022 //
PRESS RELEASE
Beam Therapeutics Announces Reports Third Quarter Financial Results
07 Nov 2022 //
PRESS RELEASE
Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data
31 Oct 2022 //
GLOBENEWSWIRE
Latham & Watkins Advises Orbital Therapeutics Partnership With Beam Therapeutics
27 Oct 2022 //
PRESS RELEASE
Prime Medicine: CRISPR 3.0 Company
24 Oct 2022 //
SEEKINGALPHA
Beam Given Average Recommendation of "Moderate Buy" by Brokerages
22 Sep 2022 //
MARKETBEAT
Beam Therapeutics: Now Is Not The Right Time To Own
15 Sep 2022 //
SEEKING ALPHA
Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare Conference
01 Sep 2022 //
PRESS RELEASE
Beam sheds more light on clinical hold slapped on gene-edited CAR-T
31 Aug 2022 //
FIERCEBIOTECH
Beam reveals what tripped off-the-shelf CAR-T as it tries to clear FDA hold
30 Aug 2022 //
ENDPTS
Why Beam Therapeutics Stock Rocketed Higher This Week
26 Aug 2022 //
FOOL
FDA hits pause on Beam`s off-the-shelf cell therapy for blood cancers
02 Aug 2022 //
MEDCITY NEWS
Revisiting Beam Therapeutics Among Collaborative Catalysts
10 Jul 2022 //
SEEKING ALPHA
Beam Will Hire 100 More Employees By End of 2022
28 Apr 2022 //
GLOBENEWSWIRE
Pfizer teams up with Beam to ship base editors straight to target tissues
11 Jan 2022 //
ENDPTS
Beam Tx Reports Progress of Ex Vivo, In Vivo Pipeline of Base Editing Drugs
09 Jan 2022 //
GLOBENEWSWIRE
Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs
12 Dec 2021 //
PRESS RELEASE
John Maraganore steps into a new role at an upstart biotech
08 Nov 2021 //
ENDPTS
Beam, Apellis partner in deal to expand gene editing`s reach
09 Jul 2021 //
BIOPHARMADIVE
Apellis, Beam ink $75M gene-editing deal for complement diseases
01 Jul 2021 //
FIERCEBIOTECH
Apellis, Beam ink $75M gene-editing deal for complement diseases
30 Jun 2021 //
FIERCEBIOTECH
Apellis and Beam Therapeutics Enter Exclusive Research Collaboration
30 Jun 2021 //
GLOBENEWSWIRE
Apellis, Beam team up to test base editing
30 Jun 2021 //
ENDPTS
Beam Therapeutics Announces Oral and Poster Presentations at 24th
27 Apr 2021 //
GLOBENEWSWIRE
Alnylam clinical development vet becomes Beam Therapeutics CMO
16 Mar 2021 //
FIERCE BIOTECH
Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer
15 Mar 2021 //
GLOBENEWSWIRE
Beam adds to drug delivery stable with $120M GuideTx buy
23 Feb 2021 //
FIERCATBIOTECH
Beam, capitalizing on stock surge, buys gene therapy tools developer for $120M
23 Feb 2021 //
BIOPHATRMADIVE
